# US 2025/0144031 A1 · Composition for treating spinal muscular atrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144031 A1
- Document ID: US20250144031A1
- Status: Published application
- Kind: A1
- Application number: 18/926,622
- Filed: 2024-10-25
- Published: 2025-05-08
- Earliest claimed: 2023-10-27
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Reto MAURER; Serge OBERDORF; Stefanie PETER; Katharina SENGER
- Web page: https://patentgrep.com/patent/US20250144031A1

## CPC

- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2813: {Inorganic compounds}
- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/79: Polymers of vinyl pyrrolidone
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are pharmaceutical compositions and dosage forms including risdiplam that are useful in the treatment of subjects having SMA. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having SMA utilizing the pharmaceutical compositions and dosage forms provided herein.

## Claims

### Claim at position 1

1-51. (canceled)

### Claim 52

A pharmaceutical composition, comprising:
(a) a compound of formula (I):
(b) crospovidone; and
(c) an acidifier selected from the group consisting of tartaric acid, citric acid, and malic acid;
wherein the pharmaceutical composition is in the form of a tablet.

### Claim 53 (depends on 52)

The pharmaceutical composition of claim 52, wherein the tablet comprises:
i) a tablet Kernel comprising:
(a) the compound of formula (I);
(b) crospovidone; and
(c) an acidifier selected from the group consisting of tartaric acid, citric acid, and malic acid; and
ii) at least one film coating.

### Claim 54 (depends on 53)

The pharmaceutical composition of claim 53, wherein the at least one film coating comprises a first film coating, wherein the first film coating directly contacts the tablet Kernel.

### Claim 55 (depends on 54)

The pharmaceutical composition of claim 54, wherein the first film coating comprises polyvinyl alcohol, and comprises less than 0.001% by weight of iron oxide.

### Claim 56 (depends on 53)

The pharmaceutical composition of claim 53, wherein the tablet comprises a second film coating, wherein the second film coating coats the first film coating.

### Claim 57 (depends on 56)

The pharmaceutical composition of claim 56, wherein the second film coating comprises iron oxide.

### Claim 58 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition further comprises a filler selected from the group consisting of microcrystalline cellulose, cellulose powder, isomalt, lactose, maltodextrin, mannitol, dibasic calcium phosphate, sorbitol, starch, calcium sulfate, and any combinations thereof.

### Claim 59 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition further comprises:
a filler selected from the group consisting of lactose, starch, maltodextrin, isomalt, microcrystalline cellulose, mannitol, sorbitol, sucrose, dextrose, dibasic calcium phosphate, calcium sulfate, and any combinations thereof,
a lubricant selected from sodium stearyl fumarate and magnesium stearate; and
a glidant.

### Claim 60 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition further comprises:
a filler, wherein the filler is microcrystalline cellulose and mannitol;
a lubricant, wherein the lubricant is sodium stearyl fumarate; and
a glidant, wherein the glidant is colloidal silicon dioxide.

### Claim 61 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition comprises less than 0.001% by weight disodium ethylenediaminetetraacetate.

### Claim 62 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition comprises less than 0.001% by weight of sucralose.

### Claim 63 (depends on 52)

The pharmaceutical composition of claim 52, wherein the acidifier is tartaric acid, and the pharmaceutical composition comprises:
between 2% and 8% by weight of the compound of formula (I); and
between 1.0% and 4.0% by weight of tartaric acid.

### Claim 64 (depends on 63)

The pharmaceutical composition of claim 63, wherein the pharmaceutical composition further comprises:
between 20% and 40% by weight of mannitol;
between 0.2% and 5.0% by weight of colloidal silicon dioxide;
between 0.2% and 5% by weight of sodium stearyl fumarate;
between 20% and 60% by weight of microcrystalline cellulose; and
between 4.0% and 8.0% by weight of crospovidone.

### Claim 65 (depends on 55)

The pharmaceutical composition of claim 55, wherein:
the acidifier is tartaric acid;
the pharmaceutical composition comprises:
between 2% and 8% by weight of the compound of formula (I); and
between 1.0% and 4.0% by weight of tartaric acid;
less than 0.001% by weight disodium ethylenediaminetetraacetate; and
less than 0.001% by weight sucralose.

### Claim 66 (depends on 65)

The pharmaceutical composition of claim 65, wherein the tablet comprises a second film coating, wherein the second film coating comprises iron oxide and coats the first film coating.

### Claim 67 (depends on 53)

The pharmaceutical composition of claim 53, wherein the acidifier is tartaric acid, and the pharmaceutical composition comprises less than 0.001% by weight disodium ethylenediaminetetraacetate; and less than 0.001% by weight sucralose.

### Claim 68 (depends on 52)

The pharmaceutical composition of claim 52, comprising:
between 2% and 8% by weight of the compound of formula (I);
between 4.0% and 8.0% by weight of crospovidone; and
less than 0.001% by weight disodium ethylenediaminetetraacetate.

### Claim 69 (depends on 53)

The pharmaceutical composition of claim 53, comprising:
between 2% and 8% by weight of the compound of formula (I);
between 4.0% and 8.0% by weight of crospovidone; and
less than 0.001% by weight disodium ethylenediaminetetraacetate;
and wherein the first film coating comprises less than 0.001% by weight of iron oxide.

### Claim 70 (depends on 52)

The pharmaceutical composition of claim 52, comprising:
(a) between 2% and 8% by weight the compound of formula (I);
(b) between 4.0% and 8.0% by weight of crospovidone;
(c) between 1.0% and 4.0% by weight of an acidifier selected from the group consisting of tartaric acid, citric acid, and malic acid;
(d) between 70% and 90% by weight of a filler selected from the group consisting of microcrystalline cellulose, cellulose powder, isomalt, lactose, maltodextrin, mannitol, dibasic calcium phosphate, sorbitol, sucrose, dextrose, hydrolyzed starch, corn starch, pregelatinized starch, calcium sulfate, and any combinations thereof,
(e) between 2.0% and 4.0% by weight of a lubricant selected from the group consisting of sodium stearyl fumarate and magnesium stearate;
(f) between 1.0% and 3.0% by weight of a glidant, wherein the glidant is colloidal silicon dioxide; and
(g) less than 0.001% by weight of disodium ethylenediaminetetraacetate.

### Claim 71 (depends on 70)

The pharmaceutical composition of claim 70, wherein the tablet comprises:
i) a tablet Kernel comprising the compound of formula (I), crospovidone, acidifier, filler, lubricant, and glidant; and
ii) at least one film coating, wherein the at least one film coating comprises a first film coating, wherein the first film coating directly contacts the tablet Kernel and comprises polyvinyl alcohol and less than 0.001% by weight of iron oxide.

### Claim 72 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition comprises:
i) a tablet Kernel comprising:
(a) between 2% and 8% by weight of the compound of formula (I);
(b) between 1.0% and 4.0% by weight of an acidifier selected from tartaric acid, citric acid, and malic acid;
(c) between 0.5% and 12.0% by weight of crospovidone;
(d) between 20% and 60% by weight of microcrystalline cellulose;
(e) between 20% and 40% by weight of mannitol;
(f) between 0.2% and 5% by weight of sodium stearyl fumarate; and
(g) between 0.2% and 5.0% by weight of colloidal silicon dioxide; and
ii) at least one film coating, wherein the at least one film coating comprises a first film coating, wherein the first film coating directly contacts the tablet Kernel and comprises less than 0.001% by weight of iron oxide.

### Claim 73 (depends on 72)

The pharmaceutical composition of claim 72, wherein the acidifier is tartaric acid, and wherein the pharmaceutical composition comprises less than 0.001% by weight disodium ethylenediaminetetraacetate and less than 0.001% by weight sucralose.

### Claim 74 (depends on 73)

The pharmaceutical composition of claim 73, wherein the tablet comprises a second film coating, wherein the second film coating comprises iron oxide and coats the first film coating.

### Claim 75 (depends on 52)

The pharmaceutical composition of claim 52, comprising about 5 mg of the compound of formula (I).

### Claim 76 (depends on 55)

The pharmaceutical composition of claim 55, comprising about 5 mg of the compound of formula (I).

### Claim 77 (depends on 63)

The pharmaceutical composition of claim 63, comprising about 5 mg of the compound of formula (I).

### Claim 78 (depends on 65)

The pharmaceutical composition of claim 65, comprising about 5 mg of the compound of formula (I).

### Claim 79 (depends on 73)

The pharmaceutical composition of claim 73, comprising about 5 mg of the compound of formula (I).
